NEW YORK, June 15, 2017 /PRNewswire/ --
Q BioMed Inc. (OTCQB: QBIO), is very pleased to announce their entry into a final license agreement with The Oklahoma Medical
Research Foundation (OMRF) and the Rajiv Gandhi Centre for Biotechnology (RGCB). Under the agreement QBioMed has the global
exclusive rights to develop and market a novel chemotherapeutic drug to treat liver cancer.
The compound was isolated and characterized from the leaves of Solanum nigrum Linn, or black nightshade, a plant widely
used in traditional medicine.
In animal models, the compound, called uttrocide B, was shown to be 10 times more cytotoxic to HepG2 liver cancer cells than
the only drug currently on the market for the condition.
"Our ultimate goal is to use uttrocide B as a chemotherapeutic against liver cancer, which has very few therapeutic options,"
said Q BioMed, Inc., CEO Denis Corin.
RGCB researchers identified the therapeutic effect of the compound and then entered into collaboration with OMRF to further
develop and commercialize it. In animal models, uttrocide B was shown to be more potent than the currently available drug for the
disease and caused no noticeable side effects.
"We are excited at the prospect of developing a drug that could address a significant unmet medical need and benefit
patients", said Dr. M.R.Pillai, Director of RGCB.
Liver cancer is the second most common cause of cancer deaths worldwide, according to the Centers for Disease Control and
Prevention, and claims approximately 750,000 lives each year. The American Cancer Society estimates that 39,000 people in the
U.S. will be diagnosed with primary liver cancer in 2017 and that 27,000 will die from the disease this year.
"This is truly an unmet need in liver cancer," said OMRF Vice President of Technology Ventures, Manu
Nair. "To find a plant-based treatment for a condition like liver cancer can open the door to a wide variety of other
natural products for treating human disease."
Please visit http://www.qbiomed.com for more information and
sign up to receive regular updates. Follow us on Twitter @QBioMed .
About OMRF
OMRF (omrf.org) is an independent, nonprofit biomedical research institute dedicated to understanding and developing more
effective treatments for human diseases. Its scientists focus on such critical research areas as cancer, diseases of aging, lupus
and cardiovascular disease.
About RGCB
RGCB is an autonomous national institution fully-owned by the Government of India. It does
pioneering research in cellular and molecular mechanisms of human animal and plant disease by amalgamating theory, modeling,
simulation and experimental science.
About Q BioMed, Inc.
Q BioMed, Inc., (Q) is a biomedical acceleration and development company. We are focused on licensing and acquiring
biomedical assets across the healthcare spectrum. Q is dedicated to providing these target assets the strategic resources,
developmental support and expansion capital they need to ensure they meet their developmental potential, enabling them to provide
products to patients in need.
Forward-Looking Statements:
This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933
and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating
to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking
statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect
our business, operating results, financial condition and stock price. Factors that could cause actual results to differ
materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research
and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and
relationships; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability
to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial
additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described
in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any
forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or
circumstances on which any such statement is based, except as required by law.
Contact:
Dennis Corin, CEO
Q BioMed Inc.
+1-888-357-2435
SOURCE Q BioMed Inc.